NuCana

NuCana is a Nasdaq-listed, clinical-stage biopharmaceutical company headquartered in Edinburgh, Scotland, focused on significantly improving treatment outcomes for patients with cancer. Founded in 2008 by CEO Hugh Griffith, the company applies its proprietary ProTide phosphoramidate technology to transform established nucleoside analogs into more effective and safer anti-cancer medicines designed to overcome key cancer resistance mechanisms. NuCana's pipeline includes candidates targeting colorectal, pancreatic, and other cancers, with the ProTide platform enabling much higher concentrations of active anti-cancer metabolites within tumor cells compared to conventional chemotherapy. The company also maintains a U.S. office in Newton, Massachusetts.